Vano Highlights Trials and Data in RCC
Yann-Alexandre Vano, MD, discusses some of the exciting data being seen in the renal cell carcinoma space.
Comparing BIONIKK Data of Nivolumab With/Without Ipilimumab in mRCC
Yann-Alexandre Vano, MD, explains some of the findings from the phase 2 BIONIKK trial which evaluated nivolumab and ipilimumab in metastatic renal cell carcinoma.
The Impact of Biomarker-Driven Frontline Treatment in mRCC
Looking at the results of the BIONIKK trial, Yann-Alexandre Vano, MD, discusses the importance of having biomarkers drive treatment decisions in patients with metastatic renal cell carcinoma.
Updated Data From the Phase 2 BIONIKK Trial in RCC
Yann-Alexandre Vano, MD, discusses the main findings from the phase 2 BIONIKK trial that were presented at the 2023 Genitourinary Cancers Symposium.
2 Commerce Drive Cranbury, NJ 08512